Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:INSM NASDAQ:NUVL NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$93.27-0.1%$95.96$79.52▼$124.00$23.54B1.361.08 million shs88,208 shsINSMInsmed$111.31+7.1%$144.00$64.85▼$212.75$24.25B0.892.58 million shs1.60 million shsNUVLNuvalent$102.82-1.7%$101.97$68.64▼$113.01$8.08B1.15558,534 shs100,404 shsRVMDRevolution Medicines$142.30-1.3%$115.02$34.00▼$155.70$30.28B1.413.45 million shs192,615 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-0.84%-4.31%-2.26%-14.31%+0.61%INSMInsmed+2.69%-22.04%-32.89%-30.06%+59.63%NUVLNuvalent-0.69%+5.56%+1.76%+2.42%+49.68%RVMDRevolution Medicines+1.65%+3.35%+49.49%+50.08%+255.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$93.27-0.1%$95.96$79.52▼$124.00$23.54B1.361.08 million shs88,208 shsINSMInsmed$111.31+7.1%$144.00$64.85▼$212.75$24.25B0.892.58 million shs1.60 million shsNUVLNuvalent$102.82-1.7%$101.97$68.64▼$113.01$8.08B1.15558,534 shs100,404 shsRVMDRevolution Medicines$142.30-1.3%$115.02$34.00▼$155.70$30.28B1.413.45 million shs192,615 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-0.84%-4.31%-2.26%-14.31%+0.61%INSMInsmed+2.69%-22.04%-32.89%-30.06%+59.63%NUVLNuvalent-0.69%+5.56%+1.76%+2.42%+49.68%RVMDRevolution Medicines+1.65%+3.35%+49.49%+50.08%+255.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.72Moderate Buy$131.6040.99% UpsideINSMInsmed 3.00Buy$211.86103.93% UpsideNUVLNuvalent 2.88Moderate Buy$137.2531.28% UpsideRVMDRevolution Medicines 3.10Buy$103.88-27.94% DownsideCurrent Analyst Ratings BreakdownLatest NUVL, RVMD, BNTX, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026INSMInsmed HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/8/2026INSMInsmed GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$230.00 ➝ $226.005/8/2026INSMInsmed Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$220.00 ➝ $205.005/8/2026INSMInsmed Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$177.00 ➝ $160.005/7/2026RVMDRevolution Medicines GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$205.005/7/2026RVMDRevolution Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$165.005/7/2026RVMDRevolution Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$165.005/7/2026RVMDRevolution Medicines Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$172.005/6/2026BNTXBioNTech Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$171.00 ➝ $158.005/6/2026BNTXBioNTech Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$150.00 ➝ $140.004/27/2026BNTXBioNTech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$130.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$3.25B7.27$1.32 per share70.50$96.59 per share0.97INSMInsmed$606.42M37.13N/AN/A$3.46 per share30.03NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ARVMDRevolution Medicines$11.58M2,646.48N/AN/A$8.44 per share17.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%N/AINSMInsmed-$1.28B-$5.75N/A74.74N/A-144.44%-130.11%-51.57%N/ANUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-41.73%-36.87%N/ARVMDRevolution Medicines-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%N/ALatest NUVL, RVMD, BNTX, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/6/2026Q1 2026RVMDRevolution Medicines-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.59 million2/25/2026Q4 2025RVMDRevolution Medicines-$1.56-$1.86-$0.30-$1.86$3.89 millionN/A2/19/2026Q4 2025INSMInsmed-$1.07-$1.54-$0.47-$1.54$263.97 million$263.84 million2/14/2026Q4 2025BNTXBioNTechN/A-$0.3870N/A-$1.47N/A$1.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74INSMInsmed0.804.474.10NUVLNuvalentN/A15.2715.27RVMDRevolution Medicines0.196.806.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%INSMInsmedN/ANUVLNuvalent97.26%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%INSMInsmed2.10%NUVLNuvalent10.20%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableINSMInsmed1,664216.75 million212.20 millionOptionableNUVLNuvalent4078.62 million74.67 millionOptionableRVMDRevolution Medicines250212.60 million195.16 millionOptionableNUVL, RVMD, INSM, and BNTX HeadlinesRecent News About These CompaniesQ2 EPS Forecast for Revolution Medicines Lowered by AnalystMay 11 at 1:05 AM | marketbeat.comRevolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for DaraxonrasibMay 10 at 7:50 PM | insidermonkey.comIs It Too Late To Consider Revolution Medicines (RVMD) After A 240% One Year Surge?May 10 at 7:06 AM | finance.yahoo.comRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $165.00May 10 at 4:19 AM | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $172.00 at Piper SandlerMay 8, 2026 | americanbankingnews.comRevolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 ExpiryMay 8, 2026 | tipranks.comRevolution Medicines Signals Breakout With RAS WinsMay 7, 2026 | tipranks.comRoyal Bank Of Canada Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $165.00May 7, 2026 | marketbeat.comRVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense ViewMay 7, 2026 | zacks.comRevolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comRevolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Wedbush Analyst SaysMay 7, 2026 | marketbeat.comPiper Sandler Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock PriceMay 7, 2026 | marketbeat.comComerica Bank Sells 466,931 Shares of Revolution Medicines, Inc. $RVMDMay 7, 2026 | marketbeat.comRevolution Medicines Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPSMay 6, 2026 | marketbeat.comRevolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic CancerMay 6, 2026 | globenewswire.comPromising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effectsMay 6, 2026 | reuters.comRevolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate ProgressMay 6, 2026 | globenewswire.comRevolution Medicines, Inc. $RVMD Shares Sold by State of New Jersey Common Pension Fund DMay 5, 2026 | marketbeat.comRevolution Medicines (RVMD) to Release Quarterly Earnings on WednesdayMay 4, 2026 | americanbankingnews.comRevolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B OpportunityMay 2, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNUVL, RVMD, INSM, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$93.27 -0.07 (-0.07%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Insmed NASDAQ:INSM$111.31 +7.42 (+7.14%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Nuvalent NASDAQ:NUVL$102.82 -1.73 (-1.66%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Revolution Medicines NASDAQ:RVMD$142.30 -1.85 (-1.28%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
